Comparative Pharmacology
Head-to-head clinical analysis: KETOTIFEN FUMARATE versus PHENETRON.
Peer-Reviewed Evidence
Head-to-head clinical analysis: KETOTIFEN FUMARATE versus PHENETRON.
KETOTIFEN FUMARATE vs PHENETRON
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Antihistamine and mast cell stabilizer; inhibits release of histamine and other mediators from mast cells; also blocks histamine H1 receptors.
Phenetron is an antihistamine that competes with histamine for H1-receptor sites, blocking histamine-mediated effects in the respiratory tract, vascular system, and gastrointestinal tract. It also exhibits anticholinergic and sedative properties.
1 mg orally twice daily; ophthalmic: 1 drop in each eye every 8-12 hours.
Adults: 50 mg intramuscularly every 6 hours as needed.
None Documented
None Documented
Terminal half-life 12-24 hours (mean 18 hours); requires twice-daily dosing after initial titration.
Terminal half-life 12–15 hours; clinically, steady-state achieved in ~3 days
Renal (50-70% as conjugates, <2% unchanged), fecal (<10%), with enterohepatic circulation.
Renal: ~70% unchanged; Biliary/Fecal: ~15% as metabolites; 15% unidentified
Category A/B
Category C
Antihistamine / Mast Cell Stabilizer
Antihistamine